Amneal Pharmaceuticals (AMRX) FCF Margin (2017 - 2026)

Amneal Pharmaceuticals' FCF Margin history runs 10 years deep, the most recent figure standing at 4.83% for Q1 2026.

• On a quarterly basis, FCF Margin fell 401.0% year-over-year to 4.83% in Q1 2026; TTM through Mar 2026 was 7.9%, a 97.0% decrease from a year earlier, with the FY2025 full-year figure at 8.94%, up 24.0% from the prior year.
• FCF Margin fell to 4.83% in Q1 2026 per AMRX's latest filing, from 13.33% in the prior quarter.
• Across five years, FCF Margin topped out at 23.32% in Q1 2023 and bottomed at 23.34% in Q2 2022.
• The 5-year median for FCF Margin is 11.25% (2023), against an average of 7.6%.
• Across the five-year window, FCF Margin surged 1945 bps in 2023 and sank 2539 bps in 2024, its largest moves.
• Year by year, FCF Margin stood at 2.2% in 2022, then soared by 830 bps to 20.42% in 2023, then plunged by 31 bps to 14.09% in 2024, then decreased by 5 bps to 13.33% in 2025, then slumped by 136 bps to 4.83% in 2026.
• Per Business Quant, the three latest AMRX FCF Margin figures stand at 4.83% (Q1 2026), 13.33% (Q4 2025), and 13.53% (Q3 2025).